CliffBio
small molecule

FINASTERIDE AND TADALAFIL

FINASTERIDE; TADALAFIL

Loss of exclusivity—loss of exclusivity
CompanyNovitium Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameFINASTERIDE AND TADALAFIL
Active ingredientFINASTERIDE; TADALAFIL
Strength5MG;5MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2025
Marketing statusRX

More from Novitium Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.